Friday, September 28, 2018—The Food and Drug Administration (FDA) has approved galcanezumab-glnm (Emgality; Lilly, Indianapolis, IN) for the prevention of migraine in adults. Galcanezumab is available a…
Stephen M. Gollomp, MD
October 2018—In this new column, we feature content from presenters at the 2018-2019 Philadelphia Neurological Society meetings.
Peter McAllister, MD
October 2018—Neurologists need to understand the phenomenon of using psychedelic drugs for cluster-busting and advocate for appropriate research.
Monday, September 17, 2018—The Food and Drug Administration (FDA) has approved fremanezumab-vfrm (Ajovy; Teva Pharmaceutical Industries, Jerusalem, Israel) for prevention of migraine in adults. Fre…
Wednesday, September 12, 2018—An investigational drug application has been filed with the Food and Drug Administration (FDA) for BHV-3500 (Biohaven, New Haven, CT). This new compound is the first intranasa…
Thursday, September 06, 2018—Data from 2 phase 3 pivotal trials of rimegepant (Biohaven, New Haven, CT) for treatment of patients with migraine will be presented at the 17th Biennial Migraine Trust Intern…
Wednesday, September 05, 2018—In a small (n = 17 men), double-blind, placebo-controlled study using a counterbalanced within-subjects design, treatment of patients with chronic neuropathic pain with d…
September 2018—A roundtable discussion with Claudia A. Chiriboga, MD, MPH; Jeffrey L. Cummings, MD, ScD; and Nir Lipsman, MD, PhD
